DEF 14A: PAVmed Inc. Seeks Stockholder Approval for Debt Restructuring and Increased Share Authorization

PAVmed Inc. is holding a special meeting to seek stockholder approval for a debt exchange, a securities purchase agreement, and an increase in authorized common stock to address Nasdaq listing requirements and financial obligations.

Summary

• PAVmed Inc. is seeking stockholder approval for several key proposals at a special meeting on January 15, 2025.
• The company aims to exchange $22,347,543 of convertible notes for Series C Preferred Stock.
• They also plan to issue additional Series C Preferred Stock in exchange for the cancellation of $2,652,456.76 of unsecured debt.
• A key proposal is to increase the authorized common stock from 50,000,000 to 250,000,000 shares.
• These actions are intended to help PAVmed regain compliance with Nasdaq listing requirements and settle liabilities.
• The company needs these approvals to proceed with the debt exchange and securities purchase agreements.
• The board recommends voting for all proposals.

Sentiment

Score: 6

Explanation: The document outlines necessary steps to improve the company's financial position and maintain its Nasdaq listing, but also highlights the risks of dilution and potential failure. The sentiment is cautiously optimistic, reflecting the need for these measures to succeed.

Positives

• The debt exchange is expected to improve the company's balance sheet by converting debt into equity.
• The cancellation of unsecured debt will preserve cash for operations.
• Increasing authorized shares will provide flexibility for future financing and strategic opportunities.
• The proposed actions are expected to help PAVmed regain compliance with Nasdaq listing requirements.
• The Series C Preferred Stock has a liquidation preference over common stock.

Negatives

• The issuance of new shares will dilute existing shareholders' ownership.
• The conversion price of the Series C Preferred Stock can be adjusted based on market conditions, potentially leading to significant dilution.
• Failure to approve the proposals could lead to delisting from Nasdaq.
• The company has a history of not paying cash dividends on its common stock.
• The company has a stockholders deficit of $9.4 million as of September 30, 2024.

Risks

• If the debt exchange and securities purchase proposals are not approved, the company may need to seek alternative financing, which may not be available on acceptable terms.
• The company may not be able to regain compliance with Nasdaq listing requirements if the proposals are not approved.
• The issuance of additional shares could negatively impact the market price of the common stock.
• The company is subject to certain financial covenants, including maintaining cash flow on a break-even basis.
• The company has a history of not paying cash dividends on its common stock.

Future Outlook

The company expects to close the transactions contemplated by the Debt Exchange Agreement and the Securities Purchase Agreement as soon as practicable after the Special Meeting. They also plan to continue seeking stockholder approval quarterly until obtained.

Management Comments

• The Board believes that it is in the best interest of the Company's stockholders to approve the issuance of shares of the Company's common stock pursuant to the Series C Preferred Stock and to increase the total number of shares of common stock the Company is authorized to issue.
• Replacing the Convertible Notes with an equity instrument is critical to the Company's plan to regain compliance with the Nasdaq continued listing requirements.
• Cancelling certain unsecured debt obligations will allow the Company to settle its liabilities while preserving cash for the operation of its business.

Industry Context

This announcement reflects a common strategy for companies facing financial challenges and Nasdaq listing compliance issues. Restructuring debt and increasing authorized shares are typical steps to improve financial stability and access to capital markets. Many companies in the biotech and medical device sectors face similar challenges.

Comparison to Industry Standards

• The use of convertible preferred stock to restructure debt is a common practice among companies seeking to improve their balance sheets, similar to companies like Sorrento Therapeutics (SRNE) and Cassava Sciences (SAVA) who have used similar instruments.
• The proposed increase in authorized shares is substantial, but not uncommon for companies needing to raise capital or issue shares for acquisitions, similar to companies like Novavax (NVAX) who have increased their authorized shares to fund operations and development.
• The company's efforts to regain Nasdaq compliance are similar to many other small-cap companies that have faced delisting notices, such as those in the biotech sector who have had to restructure their finances to meet listing requirements.
• The specific terms of the Series C Preferred Stock, including the conversion price and dividend rate, are within the range of what is seen in similar financing agreements, but the specific terms are tailored to the company's unique situation.

Stakeholder Impact

• Shareholders will experience dilution if the proposals are approved.
• Shareholders will benefit from the company's efforts to regain Nasdaq compliance.
• Employees may benefit from the company's improved financial stability.
• Creditors will have some debt obligations cancelled.
• The company's ability to raise capital may improve.

Next Steps

• Stockholders will vote on the proposals at the special meeting on January 15, 2025.
• The company will file a certificate of designations for the Series C Preferred Stock upon consummation of the agreements.
• The company will continue to seek stockholder approval quarterly until obtained.
• The company will work to regain compliance with Nasdaq listing standards by January 31, 2025.

Key Dates

Keywords

PAVmed, Stock Issuance, Debt Exchange, Series C Preferred Stock, Authorized Capital, Nasdaq Listing, Convertible Notes, Share Dilution, Securities Purchase Agreement, Stockholder Approval